Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study

References

• GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):954–976. doi:10.1016/S1474-4422(18)30322-3
   PubMed Web of Science ®Google Scholar
• Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17(1):15–22. doi:10.1046/j.1468-2982.1997.1701015.x
   PubMed Web of Science ®Google Scholar
• Hirata K, Ueda K, Komori M, et al. Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Curr Med Res Opin. 2021;37(11):1945–1955. doi:10.1080/03007995.2021.1971179
   PubMed Web of Science ®Google Scholar
• Clemow DB, Baygani SK, Hauck PM, Hultman CB. Lasmiditan in patients with common migraine comorbidities: a post hoc efficacy and safety analysis of two phase 3 randomized clinical trials. Curr Med Res Opin. 2020;36(11):1791–1806. doi:10.1080/03007995.2020.1808780
   PubMed Web of Science ®Google Scholar
• Loo LS, Ailani J, Schim J, et al. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain. 2019;20(1):84. doi:10.1186/s10194-019-1032-x
   PubMed Web of Science ®Google Scholar
• González-Hernández A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalón CM. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metab Toxicol. 2018;14(1):25–41. doi:10.1080/17425255.2018.1416097
   PubMed Web of Science ®Google Scholar
• Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010;30(10):1159–1169. doi:10.1177/0333102410370873
   PubMed Web of Science ®Google Scholar
• Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91(24):e2222–e2232. doi:10.1212/wnl.0000000000006641
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894–1904. doi:10.1093/brain/awz134
   PubMed Web of Science ®Google Scholar
• Shapiro RE, Hochstetler HM, Dennehy EB, et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain. 2019;20(1):90. doi:10.1186/s10194-019-1044-6
   PubMed Web of Science ®Google Scholar
• Sakai F, Takeshima T, Homma G, Tanji Y, Katagiri H, Komori M. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache. 2021;61(5):755–765. doi:10.1111/head.14122
   PubMed Web of Science ®Google Scholar
• Komori M, Mimura H, Tsai M, Ozeki A, Takaichi G, Wilbraham D. Safety, tolerability, and pharmacokinetics of lasmiditan in healthy Japanese and caucasian subjects. Jpn J Clin Pharmacol Ther. 2020;51(3):119–127. doi:10.3999/jscpt.51.119
   Google Scholar
• Hirata K, Matsumori Y, Tanji Y, Khanna R, Ozeki A, Komori M. Safety profile of lasmiditan in patients with migraine in an Asian population. Expert Opin Drug Saf. 2022;22(1):91–101. doi:10.1080/14740338.2022.2087630
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Komori M, Tanji Y, Ozeki A, Hirata K. Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial. Expert Opin Drug Saf. 2022;21(12):1495–1503. doi:10.1080/14740338.2022.2078302
   PubMed Web of Science ®Google Scholar
• Lamb YN. Lasmiditan: first approval. Drugs. 2019;79(18):1989–1996. doi:10.1007/s40265-019-01225-7
   PubMed Web of Science ®Google Scholar
• Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24(Suppl 1):9–160. doi:10.1111/j.1468-2982.2003.00824.x
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2001;41(9):854–861. doi:10.1111/j.1526-4610.2001.01156.x
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 suppl 1):S20–S28. doi:10.1212/wnl.56.suppl_1.s20
   PubMed Web of Science ®Google Scholar
• Lasmiditan succinate tablet [package insert; in Japanese]. Tokyo: Eli Lilly Japan K.K.; 2022.
   Google Scholar
• Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635–642. doi:10.1093/qjmed/hcg109
   PubMed Web of Science ®Google Scholar
• Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705–713. doi:10.1176/ajp.148.6.705
   PubMed Web of Science ®Google Scholar
• Hirata K, Ueda K, Ye W, et al. Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi migraine disease specific programme. BMC Neurol. 2020;20(1):274. doi:10.1186/s12883-020-01848-4
   PubMed Web of Science ®Google Scholar
• Ram CVS. Antihypertensive drugs: an overview. Am J Cardiovasc Drugs. 2002;2(2):77–89. doi:10.2165/00129784-200202020-00002
   PubMedGoogle Scholar
• Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1(1):CD002003. doi:10.1002/14651858.CD002003.pub5
   PubMedGoogle Scholar
• Diener H-C, Holle-Lee D, Nägel S, et al. Treatment of migraine attacks and prevention of migraine: guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin Transl Neurosci. 2019;3(1):1–40. doi:10.1177/2514183X18823377
   Google Scholar
• Lanteri-Minet M, Valade D, Geraud G, Lucas C, Donnet A. Revised French guidelines for the diagnosis and management of migraine in adults and children. J Headache Pain. 2014;15(1):2. doi:10.1186/1129-2377-15-2
   PubMedGoogle Scholar
• Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain. 2019;20(1):57. doi:10.1186/s10194-018-0899-2
   PubMed Web of Science ®Google Scholar
• Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013;40(suppl 3):S1–S80. doi:10.1017/S0317167100118943
   PubMedGoogle Scholar
• Headache Clinical Practice Guideline Development Committee. Clinical Practice Guideline for Headache Disorders 2021. Tokyo: Igaku-Shoin; 2021. Japanese.
   Google Scholar